| 董燕,陈俊文,阳俊,等.莫西沙星与头孢哌酮舒巴坦治疗老年心力衰竭患者铜绿假单胞菌院内感染的疗效对比观察[J].安徽医药,2018,22(2):312-315. |
| 莫西沙星与头孢哌酮舒巴坦治疗老年心力衰竭患者铜绿假单胞菌院内感染的疗效对比观察 |
| Comparative study of moxifloxacin and cefperazone-sulbactam in the treatment of nosocomial infection for pseudomonas aeruginosa in the elderly heart failure patientsDONG Yan,CHEN Junwen,YANG Jun,WANG Yeya (Department of Respiratory,Xiangyang First People′s Hospital,Hubei University of Medicine,Xiangyang,Hubei 441000,China) Abstract:Objective |
| 投稿时间：2016-12-20 |
| DOI： |
| 中文关键词: 莫西沙星 头孢哌酮舒巴坦 对比研究 铜绿假单胞菌 院内感染 心力衰竭 |
| 英文关键词: moxifloxacin cefperazone-sulbactam comparative study pseudomonas aeruginosa nosocomial infection heart failure |
| 基金项目: |
|
| 摘要点击次数: 2814 |
| 全文下载次数: 799 |
| 中文摘要: |
| 目的 探讨莫西沙星与头孢哌酮舒巴坦治疗老年心力衰竭患者铜绿假单胞菌(PA)院内感染的临床疗效及安全性。 方法 64例心力衰竭合并下呼吸道PA感染的老年患者按单纯随机分为两组,各32例。对照组给予头孢哌酮舒巴坦治疗,观察组予以莫西沙星治疗,观察两组患者治疗有效率、病原菌清除率、症状消失时间、免疫功能以及不良反应发生率。 结果 观察组总有效率93.75%,对照组81.25%,差异无统计学意义(P＞0.05)；观察组病原菌清除率90.62%,明显高于对照组68.75%,差异有统计学意义(P＜0.05)；观察组患者体温恢复时间、咳嗽消失时间、湿啰音消失时间、白细胞数恢复时间均低于对照组,差异有统计学意义(P＜0.05)；观察组CD3+、CD4+、CD4+/CD8+及NK细胞水平高于对照组,CD8+水平低于对照组,差异有统计学意义(P＜0.05)；观察组不良反应发生率为18.75%,与对照组21.88%类似,差异无统计学意义(P＞0.05)。 结论 与头孢哌酮舒巴坦比较,莫西沙星对老年心力衰竭患者PA院内感染疗效显著,安全性同等,值得临床推广应用。 |
| 英文摘要: |
| Objective To discuss the clinical efficacy and safety of moxifloxacin and cephalosporin-sulbactam in the treatment of pseudomonas aeruginosa nosocomial infection in senile heart failure patients. Methods A total of 64 heart failure complicated with pseudomonas aeruginosa infection of lower respiratory tract of elderly patients were randomly divided into the control group and study group,with 32 cases in each.The control group was treated with cefperazone-sulbactam,while the study group was given moxifloxacin.The effective rate of treatment,clearance rates of pathogens,time of disappearance of symptoms,immunologic function,incidence of adverse reactions were observed and compared between the two groups of patients.The statistical analysis was performed with the use of SPSS 17.0 software. Results The total effective rate of treatment of the study group was 93.75%,higher than 81.25% of the control group (P＞0.05).The clearance rate of pathogens was 90.62% in the study group,significantly higher than 68.75% in the control group (P<0.05).The time of recovery of body temperature,time of disappearance of cough,time of disappearance of wet rales,and time of recovery of white blood cells were shouter in the study group (P<0.05).CD3+,CD4+,CD4+/CD8+ were higher and CD8+ was lower in the study group,all with statistical significance (P<0.05).The incidence of adverse reactions was 18.75% in the study group,2.88% in the control group,and the two group were similar(P＞0.05). Conclusions Compared with cefperazone-sulbactam,moxifloxacin can achieve significant effect on treatment of nosocomial infection for pseudomonas aeruginosa in the elderly heart failure patients,safety similar,and which is worthy to be promoted in the hospital. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
